About Cleveland BioLabs (NASDAQ:CBLI)
Cleveland BioLabs, Inc. (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NASDAQ:CBLI
- CUSIP: N/A
- Web: www.cbiolabs.com
Capitalization:- Market Cap: $35.76 million
- Outstanding Shares: 11,279,000
Average Prices:- 50 Day Moving Avg: $3.15
- 200 Day Moving Avg: $3.05
- 52 Week Range: $1.22 - $5.55
P/E:- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $2.91 million
- Price / Sales: 12.36
- Book Value: $0.41 per share
- Price / Book: 7.78
Profitability:- EBITDA: ($5,710,000.00)
- Net Margins: -253.09%
- Return on Equity: -61.18%
- Return on Assets: -49.90%
Debt:- Current Ratio: 5.18%
- Quick Ratio: 5.18%
Misc:- Average Volume: 63,092 shs.
- Beta: 0.06
- Short Ratio: 2.13
Frequently Asked Questions for Cleveland BioLabs (NASDAQ:CBLI)
What is Cleveland BioLabs' stock symbol?
Cleveland BioLabs trades on the NASDAQ under the ticker symbol "CBLI."
How were Cleveland BioLabs' earnings last quarter?
Cleveland BioLabs, Inc. (NASDAQ:CBLI) released its quarterly earnings results on Monday, August, 14th. The company reported ($0.50) earnings per share for the quarter. The business had revenue of $0.21 million for the quarter. Cleveland BioLabs had a negative return on equity of 61.18% and a negative net margin of 253.09%. View Cleveland BioLabs' Earnings History.
Who are some of Cleveland BioLabs' key competitors?
Some companies that are related to Cleveland BioLabs include Navidea Biopharmaceuticals (NAVB), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Vernalis plc (VER), CytRx Corporation (CYTR), Prima BioMed Ltd (PBMD), ReNeuron Group Plc (RENE), Sunesis Pharmaceuticals (SNSS), OvaScience (OVAS), Bio-Path Holdings (BPTH), Genocea Biosciences (GNCA), Abzena PLC (ABZA), Senomyx (SNMX), Scancell Holdings Plc (SCLP), Fibrocell Science (FCSC), AEterna Zentaris (AEZS), Caladrius Biosciences (CLBS) and Oncobiologics (ONS).
Who are Cleveland BioLabs' key executives?
Cleveland BioLabs' management team includes the folowing people:
- Langdon L. Miller M.D., President
- Yakov N. Kogan Ph.D., Chief Executive Officer, Principal Financial Officer
- Andrei V. Gudkov Ph.D., Chief Scientific Officer
- Alexander Andryushechkin, Independent Director
- Anna Evdokimova, Independent Director
- Alexey Nechaev, Independent Director
- Ivan Persiyanov, Independent Director
- Randy S. Saluck J.D., Independent Director
How do I buy Cleveland BioLabs stock?
Shares of Cleveland BioLabs can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cleveland BioLabs' stock price today?
One share of Cleveland BioLabs stock can currently be purchased for approximately $3.19.
MarketBeat Community Rating for Cleveland BioLabs (NASDAQ CBLI)MarketBeat's community ratings are surveys of what our community members think about Cleveland BioLabs and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Cleveland BioLabs (NASDAQ:CBLI) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Consensus Price Target History for Cleveland BioLabs (NASDAQ:CBLI)
Analysts' Ratings History for Cleveland BioLabs (NASDAQ:CBLI)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Cleveland BioLabs (NASDAQ:CBLI)Earnings History by Quarter for Cleveland BioLabs (NASDAQ CBLI)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/14/2017 | Q2 2017 | | ($0.50) | | $0.21 million | View | N/A |  |
| 5/15/2017 | Q1 2017 | | ($0.15) | | $0.58 million | View | N/A | |
| 2/22/2017 | Q4 2016 | | ($0.11) | | $0.99 million | View | N/A | |
| 8/15/2016 | Q2 | | ($0.17) | | $0.58 million | View | N/A | |
| 5/16/2016 | Q116 | | ($0.06) | | $0.81 million | View | N/A | |
| 11/5/2015 | Q315 | | $0.31 | $415.00 million | $0.50 million | View | N/A | |
| 8/12/2015 | Q215 | | ($0.72) | $562.10 million | $329.90 million | View | Listen | |
| 5/6/2015 | Q115 | | ($1.14) | $1.33 million | $0.61 million | View | N/A | |
| 2/24/2015 | Q114 | | ($1.02) | $3.87 million | $1.39 million | View | N/A | |
| 3/11/2014 | Q413 | ($0.12) | ($0.01) | $1.74 million | $3.87 million | View | N/A | |
| 11/6/2013 | Q313 | ($0.14) | ($0.09) | $1.61 million | $1.60 million | View | N/A | |
| 8/13/2013 | Q2 2013 | ($0.16) | ($0.07) | $1.48 million | $1.60 million | View | N/A | |
| 5/9/2013 | Q1 2013 | ($0.17) | ($0.22) | $1.73 million | $1.37 million | View | N/A | |
| 11/8/2012 | Q312 | ($0.02) | ($0.30) | $23.87 million | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Cleveland BioLabs (NASDAQ:CBLI)No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Cleveland BioLabs (NASDAQ:CBLI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Cleveland BioLabs (NASDAQ:CBLI)Insider Ownership Percentage: 2.44%
Institutional Ownership Percentage: 4.58%
Insider Trades by Quarter for Cleveland BioLabs (NASDAQ:CBLI)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 2/25/2015 | Randy S Saluck | Director | Buy | 1,891 | $3.42 | $6,467.22 | |
| 5/21/2013 | Paul E Dicorleto | Director | Buy | 6,210 | $1.61 | $9,998.10 | |
| 5/17/2013 | Randy S Saluck | Director | Buy | 3,500 | $1.60 | $5,600.00 | |
| 3/15/2013 | James Antal | Director | Buy | 3,700 | $1.56 | $5,772.00 | |
| 9/21/2012 | James Antal | Director | Buy | 2,316 | $2.60 | $6,021.60 | |
(Data available from 1/1/2013 forward)
Headline Trends for Cleveland BioLabs (NASDAQ:CBLI)
Latest Headlines for Cleveland BioLabs (NASDAQ:CBLI)
| Source: |
|
| Date | Headline |
|---|
 | Head to Head Survey: Curis (CRIS) and Cleveland BioLabs (CBLI)
www.americanbankingnews.com - October 13 at 8:32 PM |
 | ETFs with exposure to Cleveland BioLabs, Inc. : October 11, 2017
finance.yahoo.com - October 11 at 6:31 PM |
| ETFs with exposure to Cleveland BioLabs, Inc. : September 19, 2017
finance.yahoo.com - September 19 at 10:01 PM |
| Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017
finance.yahoo.com - September 18 at 5:17 PM |
| Contrasting Cleveland BioLabs (CBLI) and Asterias Biotherapeutics (AST)
www.americanbankingnews.com - September 17 at 2:31 AM |
| What You Must Know About Cleveland BioLabs Inc’s (CBLI) Risks
finance.yahoo.com - September 11 at 5:34 PM |
| Cleveland BioLabs, Inc. (CBLI) Posts Earnings Results
www.americanbankingnews.com - August 15 at 9:41 AM |
| Cleveland Biolabs Countermeasure for Acute Radiation Syndrome, Pipeline Review, and Market Potential
finance.yahoo.com - August 11 at 5:26 PM |
| ETFs with exposure to Cleveland BioLabs, Inc. : August 4, 2017
finance.yahoo.com - August 4 at 10:18 PM |
| ETFs with exposure to Cleveland BioLabs, Inc. : July 12, 2017
finance.yahoo.com - July 12 at 5:35 PM |
 | Cleveland BioLabs Reports First Quarter 2017 Financial Results and Development Progress
feeds.benzinga.com - May 15 at 8:01 AM |
 | Gainers & Losers Of Apr.19: SNGX, IMGN, CBLI, SSH, AKTX...
www.finanznachrichten.de - April 19 at 11:03 PM |
 | Cleveland BioLabs, Inc. (CBLI) Stock Tacks On Another 40%-Plus
investorplace.com - April 19 at 3:33 PM |
 | Cleveland Biolabs (CBLI) to Begin In Vivo Bio-Comparability Study Following FDA Review
www.streetinsider.com - April 19 at 1:01 PM |
| CLEVELAND BIOLABS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
biz.yahoo.com - February 22 at 9:21 PM |
| Cleveland Biolabs (CBLI) Announces $1.1M JWMRP Contract Modification with U.S. DoD
www.streetinsider.com - October 12 at 8:37 AM |
 | BRIEF-Cleveland BioLabs announces a $1.1 mln cost realignment with Department of Defense
www.reuters.com - October 11 at 4:13 PM |
| CLEVELAND BIOLABS INC Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - July 22 at 4:22 PM |
| CLEVELAND BIOLABS INC Files SEC form 8-K/A, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta
biz.yahoo.com - July 21 at 6:05 AM |
| CLEVELAND BIOLABS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Stand
biz.yahoo.com - July 12 at 4:25 PM |
 | 22nd Century to begin cannabis research at new medical campus labs
www.bizjournals.com - May 12 at 2:40 PM |
| CLEVELAND BIOLABS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibit
biz.yahoo.com - May 6 at 5:55 PM |
| CLEVELAND BIOLABS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
biz.yahoo.com - April 15 at 3:05 PM |
 | GLPG Awaits SAPHIRA Data, VTAE Vaults, CBLI Hits A Snag
www.rttnews.com - March 17 at 2:04 AM |
| CLEVELAND BIOLABS INC Files SEC form 8-K, Other Events
biz.yahoo.com - March 16 at 2:50 PM |
| Hottest Services Stocks Now – CAI NEWT INST MOBL
investorplace.com - March 8 at 11:42 AM |
| CLEVELAND BIOLABS INC Files SEC form 10-K, Annual Report
biz.yahoo.com - February 23 at 5:04 PM |
| CLEVELAND BIOLABS INC Files SEC form 8-K, Results of Operations and Financial Condition
biz.yahoo.com - February 22 at 10:35 AM |
| Cleveland BioLabs, Inc. (CBLI)
biz.yahoo.com - February 18 at 6:31 PM |
| Hottest Services Stocks Now – ADUS SREV EBIX CBLI
investorplace.com - February 9 at 10:47 AM |
| Cleveland Biolabs (CBLI) Says Entolimod Shown to Suppress Metastasis and Induce Immunity by Stimulating NK-Dendritic-CD8+ T cell Axis
www.streetinsider.com - February 9 at 10:47 AM |
Cleveland BioLabs (CBLI) Chart for Wednesday, October, 18, 2017
